Acquisition Pending
Angelini Pharma S.p.A. acquisition of Catalyst Pharmaceuticals
US$4.1bn equity value
Announced 7 May 2026 · NASDAQ: CPRX · US$31.50 cash per share
Advisers
Catalyst Pharmaceuticals
Target
- Financial adviser
- Legal adviser
- Fairness opinion
Angelini Pharma S.p.A.
Acquirer
- Financial adviser
- BNP Paribas (co)Morgan Stanley
(co) - Legal adviser
- Gatti Pavesi Bianchi Ludovici (as Gatti, Pavesi, Bianchi, Ludovici Studio Legale)
- Target
- Catalyst Pharmaceuticals
- Acquirer
- Angelini Pharma S.p.A.
- Target based in
- United States
- Buyer based in
- Italy
- Sector
- Pharma
- Tags
- Pharma, Rare Disease
In the league tables
- M&A financial advisers, 2026 to date J.P. Morgan #1 · Centerview Partners #5 · Morgan Stanley #6 · BNP Paribas #30
- M&A legal advisers, 2026 to date Kirkland & Ellis #1 · Hogan Lovells Cadwalader #26 · Akerman #78 · Gatti Pavesi Bianchi Ludovici #85
- Fairness opinion providers, 2026 to date J.P. Morgan #1
Similar deals
- BioMarin acquisition of Amicus Therapeutics Dec 2025 · US$4.8bn · Biotech
- Neurocrine Biosciences acquisition of Soleno Therapeutics Apr 2026 · US$2.9bn · Biotech
- Chiesi Group acquisition of KalVista Pharmaceuticals Apr 2026 · US$1.9bn · Pharma
- Vertex Pharmaceuticals acquisition of Crinetics Pharmaceuticals Jul 2026 · US$10bn · Biotech
- ANI Pharmaceuticals acquisition of Egetis 2026 · US$560m · Pharma
Sources
- 2026 Centerview Partners: Lead financial advisor to Angelini Pharma on its acquisition of Catalyst Pharmaceuticals centerviewpartners.com
- May 2026 Kirkland Advises Catalyst Pharmaceuticals on $4.1 Billion Sale to Angelini kirkland.com
- 7 May 2026 Press release (EX-99.1, exhibit), Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), sec.gov
- 8 Jun 2026 Definitive merger proxy statement (DEFM14A), CATALYST PHARMACEUTICALS, INC. sec.gov



